I have no problem using aminoglycoside-containing topieal antibiotic drops in the presence of an intact tyrnpanic membrane. However, a major problem could arise when a patient has a defect in a tympanic membrane-for example, a ventilation tube or a perforation-that might allow these drops to be absorbed into the inner ear via the round window membrane. Under these circumstances, I prefer to use a topieal quinolone, which in my practice has been every bit as effective.
If there is no alternative but to use an aminoglycoside, then I do so carefully; I prescribe it for the shortest duration necessary and certainly for no longer than 5 or 7 days without reviewing the patient clinically to see if further treatment is required. Implicit is the fact that patients on topieal aminoglycoside drops must be warned about their adverse effects and be instructed to stop the drops immediately if any dizziness, imbalance, hearing loss, or tinnitus occurs during therapy. Our experience with inadvertent topieal gentamicin vestibulotoxicity (which is described in detail below) revealed that the earliest toxicity occurred on day 7 of treatment. In our study of intentional gentamicin toxicity in patients with incapacitating unilateraI Menieres disease, the earliest we recognized a deafferentation was approximately day 9. The longer these drops are used, the more likely toxicity will occur.
In general, ototoxic drugs should not be used in a patient whose middle eal' is dry. They should be used only in infected ears. One exception might be for a patient with a perforated tympanic membrane who allowed some water into the ears by accident; even then , they should be used for only a short duration.
Clinieal studies of topieal gentarniein ototoxicity
At the University of Toronto, we discovered that the topieal aminoglycoside gentamicin was ototoxic to the vestibular portion of the eal' back in the 1980s. At that time, we were treating patients who had incapacitating unilateraI Meniere' s disease with high-concentration intratympanic gentamicin.We would inject approximately 24 mg/ml of gentamicin three times a day for 3 days through a piece of butterfly catheter tubing that had been inserted into the eardrum. This regimen was very successful in controlling vertigo in these patients. We often found , however, that approximately 2 days after the completion of treatment, patients would suddenly become vertiginous.
Delayed ototoxicity. In an effort to explain this delayed reaction, we surmised that the aminoglycoside would have had to pool in the area around the round window niche before it was absorbed through the round window membrane. It would then travel through the cochlea and eventually into the labyrinth, where it did its damage. Additionally, many of these patients would experience a high-frequency hearing loss , which was not surprising considering the proximity of the basal turn of the cochlea to the round window membrane.
To demonstrate topieal toxicity, we performed caloric testing on 24 patients before and after they had undergone gentamicin ablation. We believed that this would be an objective method of determining what occurred in the inner ear as measured by changes in the caloric excitability difference. At study 's end, we found that 18 of these patients (75 %) experienced a statistically significant deafferentation of vestibular function ( figure) . ' In the meantime, we saw some patients in consultation who had discharging ears that had been treated with a lowconcentration topieal antibiotic/steroid combinationspecifically,3 mg/ml of gentamicin and I mg/mlofbetamethasone. Three of these patients had complaints of ataxia, imbalance, and oscillopsia. Their history revealed that all three had taken their gentamicin/betamethasone drops for 2 to 3 weeks , eve n after their ears had become dry . This prolonged exposure to the drug led to bilateral vestibulotoxicity. Because we did not have any pretreatment audiometric or vestibular data on these early patients , we could not prove what we believed. Nevertheless, we were certain that a commercially available topieal gentamicin preparation-with OI' without a steroid-became ototoxic after an average of 2 weeks ' use. Since then, we have identified incontrovertible evidence of topieal gentamicin toxicity in approximately 30 more patients. 
Dr. Schapowa l:
As far as bacterial infections are concerned, I do not see any reason to use an ototoxic topieal antibiotic as a first-line treatment. Not only do these agents pose safety prob Iems, but they also are simply less effective than quinolones. The onlyargument one could make for ototoxic agents is that they are inexpensive, and this would be avalid consideration in underdeveloped countries.
In patients with a perforated tympanic membrane, ototoxic effects can occur after only a sing le dose, regard Iess of how small the perforation is. So if you do use an ototoxic drop in an open eardrum, you should inform the patient of the risk and you should perform audiometry before and after treatment. If patients begin to notice a loss of hearing while on therapy, they should report it immediately and should undergo audiometry as soon as possible. If a patient cannot undergo audiometry within 24 hours, he or she should stop taking the medication until a visit can be scheduled.
Before ciprofloxacin/hydrocortisone otic solution became available, I would use ciprofloxacin eyedrops to treat middle ear infections in patients who had a perforated tympanic membrane, as weil as in patients who had external otitis. Ciprofloxacin/hydrocortisone drops seldom fail, and they are especially effective against problematic bacteriasuch as Pseudomonas aeruginosa .Therefore, Iuse ototoxic eardrops only as a second-line therapy and only in patients who have an intact tympanic mernbrane.
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Genetic predis position
Fina lly, in what is something of a disconcerting development, we have learned that so me Asian and Middle Eastern patient groups appear to be exquisitely sensitive to the aminoglycoside kanamycin because they have a mitochondrial RNA mu tation . People with this genetic mutation are at risk of completely losing their hearing and possibly their vestibular function after one or two doses. As peop le continue to move around the world in greater numbers, it' s possible that you might see such a patient in your office.
Discussion
Dr. Roland: Does anyone else feel comfortable using "Therapeutic ototoxicity." In light of our findings with inadvertent gentamicin ototoxicity, we decided to study the feasibility of inducing intentional vestibulotoxicity with the same low-concentration gentamicin/betamethasone preparation in patients with incapacitating Menieres disease. In an ongoing study , we have thus far treated 37 patients. We insert a ventilation tube into the ear and _ teil patients to instill 3 drops four times a day until they begin to experience dizziness, and then to continue the drops for 2 more days .
After the 2 days, they were instructed to stop taking the medication. Electronystagmography and audiometry were performed before and after each patient' s treatment course .
We found that most patients experienced ototoxicity 12 days into their trea tment regimen. The onset of vertigo in these patients occurred more rap idly than it did in the patients with discharging ears who experienced inadvertent ototoxicity as they had become dizzy after an average of 14 or 15 days of treatment. The reason for the 2-or 3-day difference was that the otorrhea in the latter 'group had prevented the drops from reaching the middle ear space right away. Once the otorrhea subsided, the drops were in a situation where they could be absorbed into the inner ear.
Of the 37 patients, approximately 75% have exhibited a significant change in caloric excitability difference. AIso , approximately 50% of patients experienced a worsening of their hearing, which ind icates that patients with Menieres disease might be more sensitive to the effects of gentamicin. Approximately 40% of our patients developed permanent perforations in their eardrums once their tubes had been extruded, which might possibly be explained as a resultof the steroid component. Last year, we . published an article reporting the results of intentional ablation in 20 of these patients.?
Also, antimycotic topieal treatment is required for the 4% of cases of external otiti s that are caused by fungi. In these patients, I have achie ved good results with natamyc in.
Dr. Haynes: I see no reason to use an aminoglycosidecontaining drop when we have a safe altern ative . I don't have an alternative to gentian violet or acetic acid, and I occasionally have to use them . But I won' t use an arninoglycoside-containing eardrop, becau se the quin olone drop s are available.
Prof. Hawke: On e thing you do not want to do is continue to put aminoglycoside drop s into a normal middle ear. If you do , there is a stron g likelihood that ototoxicity will develop sornetime after 7 day s.
Dr. Roland: When you prescribe any drug for otorrhea , do you instruct the patient to use it for a specific number of days, or until the drain age stops, or for a specified number of day s after the resolution of drain age ? Many of my partners instruct patient s to take their drops until the drainage stops and then for 1 additional day.
Dr. Dohar: We teIl all otorrhea patient s, regardless of which drug they are taking , to take their drops for 7 days and then return for a follow-up visit. We don 't rely on patients to subjectively asse ss otorrhea , becau se their evaluations don't correlate well with otoscopic documentation. Also, with ofloxacin drops, we ha ve found that 3 or 5 days of treatment is inadequate ; in fact, it' s no better than placebo. A minimum of7 days is nece ssary. I don 't know if the duration would be different with another antibiotic or with the addition of a steroid.
Dr. Rutka: I would stop the drop s shortly after the drainage resolves, I would not continue them for any longer than 48 hours.
Dr. Roland: Doe s anyone support the use of ototoxic antibiotics ju st because they're inexpensive? Dr. Rutka: In the ideal world, of course, cost would not be an issue, and safety and efficacy would reign supreme. Nevertheless, if you are conside ring treating a patient with a potentially ototoxic drug for long er than 1 week, I would stro ngly suggest that you reconsider and choose an alternative. Remember that if a patient doe s develop ototo xicity, the money you saved by pre scribing a lessexpensive ototoxic drug will be outweighed by the adverse effects on the patient and the con sequences of possible medicolegal action.
Dr. Manning: It' s not that I support their use as much as I have no choice but to use them. In most urban cent ers in the United States, approximately 50 % of the patients in a children 's hospital are on Medicaid, and Med icaid doe sn ' t co ver the more expensive, patented drug s if there is a generic available. The refore, the onl y available options might be neomycin drop s-which we never use becaus e of their ototoxicit y and low pH, and becau se they sting the skin-and a generic antibiotic such as gentamicin. When forced to use an ototoxic drop , we tell the patient not to take it for more than 5 to 7 days and not to take it once the otorrh ea resolves. It' s quite a dilemma when the only treatment available is one that we might be sued for prescribin g, Dr. Dohar: We have a similar situation at the Children' s Hospit al of Pitt sburgh in that we see perhaps 95% of the indigent population in our area. We have asked thirdpart y payers to put a quinolone on their formul ary, but they will not do it. So for these patients, we have no choice but to use an ototoxic drug.
Dr. Roland: Like Dr. Schapowal, we at the University of Texas Southwestern have been able to bypas s formular y restrictions by prescribing an ophthalmic quinolone, and these eyedrops are on most formularies. But that' s ju st skirting the real issue. Our profession must continue to emphasize to managed care organi zations that the use of ototoxic drugs is not good medicineo Dr. Haynes: Would a position statement from the AAO-HNS impro ve our aecess to nonototoxic eardrops?
Dr. Roland: Such a statement would put pressure on insurance companies, but the extent to which they would fight or succumb to that pre ssure would depend on internal factors beyond ju st medical safety. Insurance companies don 't have to do anything. They can simply say , "Sorry, we dori't agree with you ." But the fact remains that we face a dilemma in that our patients must choose between generics, which are les s expensive but more dangerous, and quinolones, which are more expen sive but safer.
Dr. Poole: Our respon sibility is not to make economic dec isions for our patients. Our responsibility is to inform them of the risks and benefits of the different therapeutic options. If they want to spend $8 rather than $40, that' s their deci sion. All we can do is give them the fact s.
Dr. Roland: Which bring s us to informed consent. A failure to obtain inform ed cons ent is frequently the pivotal point in malpr actice lawsuit s. What do you tell your patients when you prescribe an ototoxic drug because you know they can 't afford anything else ?
Dr. Manning: Every treatment deci sion we make invol yes a risk and a benefit. Th at' s the nature ofmedicine. When you're treating a patient for a dra ining ear and you know he doesn't have much mon ey, the risk of doing nothing is greaterthan the risk of ototoxicity. But we must explain the risks as best we can and we must do whatev er it take s to obtain inform ed consent.
Dr. Rutka: It would be good practice to inform patients of the risks of amin oglycoside-containing drops , but we should ack nowledge that the likelihood of ototoxicity is extremely low during a limited treatment course. As Dr. Manning suggested , untreated disease also carries risks for sensorineural hearing los s as well as vestibular loss.
Dr. Dohar: We have a standard printed form that we ask patients to read and sign, and we keep it in their chart. RUTKA The form says that there is a risk that the drug will cause permanent injury to either the hearing organ or the balance organ, although the risk is very small. We define small as less than 5%. We also put alimit on the duration of therapy , even though, as Dr. Schapowal and Dr. Rutka have pointed out, an ototoxic drug can cause hearing loss after only a single dose.
Dr. Haynes: How do you feel about the issue of informed consent for eardrops? I have seen articles in the Canadian literature recommending that patients should be informed of the potential risks of aminoglycoside eardrops. This certainly is new ground.
Dr. Roland: I don't believe the consensus panel will make any recommendation as to whether consent should be written or oral. All prescribers are already required by law to inform patients of the risks and complications of any treatment, although we haven't been very conscientious about doing this for oral medications. On the other hand, I know that some rheumatologists are very careful when they prescribe methotrexate or cycIophosphamide for autoimmune inner ear disease, and they obtain consent after a fairly detailed discussion.
Dr. Dohar: If the AAO-HNS does formally establish guidelines for informed consent, I believe the American Academy of Family Practice and the American Academy of Pediatrics will follow suit.
Dr. Roland: Should we warn patients to call or return to the office if certain syrnptoms arise? I am aware of two lawsuits that have been filed because a patient complained of vertigo while taking drops, but the otolaryngologist didri't discontinue therapy because he didn't make the connection.
Prof. Hawke: There are two similar lawsuits in Canada in which a patient complained of dizziness, but the otolaryngologist said that it could not be caused by the drops, and he told the patient to continue them. We have a significant physician education problem , especially when you consider that in the United States , most eardrops are prescribed by physicians other than otolaryngologists.
Dr. Rutka: Other symptoms of concern are imbalanee, worsening hearing loss, and tinnitus . If they occur, the 12 • Volume 82 • Suppl 2 patient should stop the drops immediately and be reassessed at the earliest opportunity.
Dr. Roland: When you do prescribe an ototoxic antibiotic, how do you monitor the patient? Do you perform audiometry every week or two?
Dr. Coates: That would be ideal, but in the poorer areas of Australia, it's difficult to achieve . We are forced to prescribe ototoxic drugs in charity cases, but we can't know whether these patients are taking them correctly. Furthermore, patients out in the rural areas don't always return for scheduled follow-up visits.
Dr. Rutka: I'm not sure that we actually can monitor patients. We can warn them and advise them, but we can't really watch over them. It is impraetieal to perform e1ectronystagmography on every patient during therapy. And it would be nice if we could obtain a pretreatment audiogram, or at least some audiometry to use for comparison purposes, but this, too, is very difficult. Our lack of pretreatment baseline and follow-up data is one of the reasons it is difficult to know whether it is the drops, the disease process, or some other factors that might account for any cochleovestibular loss.
Some places have built-in safeguards. In England, physicians cannot prescribe an aminoglycoside drop for longer than 7 days, and they cannot renew the prescription without seeing the patient again. For many years in Canada, we did not pay too much attention to ototoxicity. In all fairness, it doesn't occur very often, but when it does, it can be serious. About 5 years ago, our national health agency also put a 7-day limit on aminoglycoside drops . But last year, the agency basically banned the use of these drops in patients with perforated eardrums. Such use is now indefensible in a court of law.
